New trial designs and potential therapies for pulmonary artery hypertension.
暂无分享,去创建一个
T. Fleming | N. Stockbridge | D. Stewart | F. Grimminger | R. Barst | C. Ventura | M. Gomberg-Maitland | T. Bull | R. Saggar | Amany Elgazayerly | M. Rainisio | A. Ghofrani | L. Rubin
[1] G. Stone,et al. TCT-683 Pulmonary artery denervation to treat pulmonary arterial hypertension: a single-center, prospective, first-in-man PADN-1 study , 2013 .
[2] G. Stone,et al. Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). , 2013, Journal of the American College of Cardiology.
[3] H. Ghofrani,et al. Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study , 2013, Circulation.
[4] S. Archer,et al. Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension , 2013, Pulmonary circulation.
[5] S. Said. Vasoactive intestinal peptide in pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.
[6] M. Humbert,et al. Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.
[7] T. Fleming,et al. Biomarkers and surrogate endpoints in clinical trials , 2012, Statistics in medicine.
[8] M. Böhm,et al. Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. , 2012, Journal of the American College of Cardiology.
[9] T. Welte,et al. Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation. , 2012, American journal of respiratory and critical care medicine.
[10] J. Loscalzo,et al. Aldosterone Inactivates the Endothelin-B Receptor via a Cysteinyl Thiol Redox Switch to Decrease Pulmonary Endothelial Nitric Oxide Levels and Modulate Pulmonary Arterial Hypertension , 2012, Circulation.
[11] D. Stewart,et al. Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension. , 2012, The American journal of cardiology.
[12] M. Humbert,et al. Résultats tardifs de la commissurotomie mitrale percutanée à 20 ans Création et validation d ’ un score de risque prédisant les résultats fonctionnels à long terme à partir d ’ une série de 912 patients , 2012 .
[13] D. Brodie,et al. Venovenous extracorporeal membrane oxygenation using a single cannula in patients with pulmonary hypertension and atrial septal defects. , 2012, The Journal of thoracic and cardiovascular surgery.
[14] M. Humbert,et al. Inflammation in pulmonary arterial hypertension , 2003, European Respiratory Journal.
[15] H. Tan,et al. Right ventricular pacing improves haemodynamics in right ventricular failure from pressure overload: an open observational proof-of-principle study in patients with chronic thromboembolic pulmonary hypertension. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[16] N. Leidy,et al. Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[17] Elizabeth Molsen,et al. Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2--assessing respondent understanding. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[18] S. Keshavjee,et al. Impact of extracorporeal life support on outcome in patients with idiopathic pulmonary arterial hypertension awaiting lung transplantation. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[19] S. Archer,et al. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle’s cycle , 2011, Journal of Molecular Medicine.
[20] Katherine Odem-Davis,et al. Some essential considerations in the design and conduct of non-inferiority trials , 2011, Clinical trials.
[21] D. Brodie,et al. Use of bicaval dual-lumen catheter for adult venovenous extracorporeal membrane oxygenation. , 2011, The Annals of thoracic surgery.
[22] H. Ghofrani,et al. Targeting non-malignant disorders with tyrosine kinase inhibitors , 2010, Nature Reviews Drug Discovery.
[23] N. Voelkel,et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. , 2010, American journal of respiratory and critical care medicine.
[24] T. Welte,et al. Extracorporeal Membrane Oxygenation in Nonintubated Patients as Bridge to Lung Transplantation , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[25] L. Rubin,et al. Editor's response to "ethical issues associated with globalization of placebo-controlled trials in pulmonary arterial hypertension". , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[26] H. Farber,et al. Ethical issues associated with globalization of placebo-controlled in pulmonary arterial hypertension. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[27] Christine M. Micheel,et al. Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease , 2010 .
[28] J. Barberà,et al. Effects Of Inhaled Aviptadil (Vasoactive Intestinal Peptide) In Patients With Pulmonary Arterial Hypertension (PAH) , 2010, ATS 2010.
[29] B. Hasinoff. The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. , 2010, Toxicology and applied pharmacology.
[30] M. Maitland,et al. A Dosing/Cross‐Development Study of the Multikinase Inhibitor Sorafenib in Patients With Pulmonary Arterial Hypertension , 2010, Clinical pharmacology and therapeutics.
[31] K. Coombes,et al. Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. , 2010, The Journal of clinical investigation.
[32] F. Grimminger,et al. PDGF receptor and its antagonists: role in treatment of PAH. , 2010, Advances in experimental medicine and biology.
[33] M. Humbert,et al. Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22α‐targeted overexpression of the serotonin transporter , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[34] Theo Arts,et al. Right ventricular free wall pacing improves cardiac pump function in severe pulmonary arterial hypertension: a computer simulation analysis. , 2009, American journal of physiology. Heart and circulatory physiology.
[35] A. Malik,et al. Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. , 2009, The Journal of clinical investigation.
[36] N. Weissmann,et al. Cellular and molecular basis of pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.
[37] E. Braunwald,et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. , 2009, Journal of the American College of Cardiology.
[38] T. Welte,et al. Bridge to Thoracic Organ Transplantation in Patients with Pulmonary Arterial Hypertension Using a Pumpless Lung Assist Device , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[39] C. Zielinski,et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] J. Behr,et al. Inhalation of vasoactive intestinal peptide in pulmonary hypertension , 2008, European Respiratory Journal.
[41] S. Srinivas,et al. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] M. Gomberg-Maitland. Traditional and alternative designs for pulmonary arterial hypertension trials. , 2008, Proceedings of the American Thoracic Society.
[43] P. Hassoun,et al. Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. , 2008, American journal of respiratory and critical care medicine.
[44] M. Halushka,et al. Heart failure associated with sunitinib malate , 2008, Cancer.
[45] J. Zwanenburg,et al. Interventricular mechanical asynchrony in pulmonary arterial hypertension: left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underfilling. , 2008, Journal of the American College of Cardiology.
[46] Thomas R Fleming,et al. Current issues in non‐inferiority trials , 2008, Statistics in medicine.
[47] P. McNamara,et al. Acute vasodilator effects of Rho-kinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide. , 2008, American journal of physiology. Lung cellular and molecular physiology.
[48] David Zurakowski,et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib , 2007, The Lancet.
[49] M. Humbert,et al. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension , 2007, European Respiratory Journal.
[50] R. A. Etten,et al. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition , 2007, Nature Reviews Cancer.
[51] Y. Shang,et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. , 2007, Journal of the American College of Cardiology.
[52] Michael L Maitland,et al. Terminal Ballistics of Kinase Inhibitors: There Are No Magic Bullets , 2006, Annals of Internal Medicine.
[53] A. Yao,et al. Upregulated neurohumoral factors are associated with left ventricular remodeling and poor prognosis in rats with monocrotaline-induced pulmonary arterial hypertension. , 2006, Circulation journal : official journal of the Japanese Circulation Society.
[54] Brian Walters,et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.
[55] S. Goldsmith. Vasopressin receptor antagonists: mechanisms of action and potential effects in heart failure. , 2006, Cleveland Clinic journal of medicine.
[56] P. Pacaud,et al. Rho kinases in cardiovascular physiology and pathophysiology. , 2006, Circulation research.
[57] M. Humbert,et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. , 2006, Gastroenterology.
[58] Daniela S Krause,et al. Tyrosine kinases as targets for cancer therapy. , 2005, The New England journal of medicine.
[59] D. Stewart,et al. Rescue of Monocrotaline-Induced Pulmonary Arterial Hypertension Using Bone Marrow–Derived Endothelial-Like Progenitor Cells: Efficacy of Combined Cell and eNOS Gene Therapy in Established Disease , 2005, Circulation research.
[60] H. Shimokawa,et al. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. , 2005, American journal of respiratory and critical care medicine.
[61] P. Rycus,et al. Extracorporeal Life Support Registry Report 2004 , 2005, ASAIO journal.
[62] J. Dyck,et al. Dichloroacetate Prevents and Reverses Pulmonary Hypertension by Inducing Pulmonary Artery Smooth Muscle Cell Apoptosis , 2004, Circulation research.
[63] K. Morris,et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. , 2004, American journal of physiology. Lung cellular and molecular physiology.
[64] R. Naeije,et al. Increased Sympathetic Nerve Activity in Pulmonary Artery Hypertension , 2004, Circulation.
[65] K. Kaibuchi,et al. Long-Term Treatment With a Rho-Kinase Inhibitor Improves Monocrotaline-Induced Fatal Pulmonary Hypertension in Rats , 2004, Circulation research.
[66] G. Berry,et al. Simvastatin Rescues Rats From Fatal Pulmonary Hypertension by Inducing Apoptosis of Neointimal Smooth Muscle Cells , 2003, Circulation.
[67] J. Halperin,et al. Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality. , 2003, American heart journal.
[68] G. Funk,et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. , 2003, The Journal of clinical investigation.
[69] Benoît Rondelet,et al. Single-beat estimation of right ventricular end-systolic pressure-volume relationship. , 2003, American journal of physiology. Heart and circulatory physiology.
[70] R. Pazdur,et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[71] T. Giles,et al. Adenoviral gene transfer of endothelial nitric-oxide synthase (eNOS) partially restores normal pulmonary arterial pressure in eNOS-deficient mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[72] Alex Matter,et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.
[73] M. Humbert,et al. CX3C Chemokine Fractalkine in Pulmonary Arterial Hypertension , 2002 .
[74] R. Pazdur,et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[75] Y. Takanashi,et al. The Effects of Vasoactive Intestinal Peptide on Monocrotaline Induced Pulmonary Hypertensive Rabbits following Cardiopulmonary Bypass: A Comparative Study with Isoproteronol and Nitroglycerine , 2002, Cardiovascular surgery.
[76] R. Schilsky. End points in cancer clinical trials and the drug approval process. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[77] M. Humbert,et al. Chemokine RANTES in severe pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.
[78] J. Dyck,et al. Dichloroacetate, a Metabolic Modulator, Prevents and Reverses Chronic Hypoxic Pulmonary Hypertension in Rats: Role of Increased Expression and Activity of Voltage-Gated Potassium Channels , 2002, Circulation.
[79] M. Humbert,et al. CX(3)C chemokine fractalkine in pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.
[80] Liang Li,et al. Rho-kinase activation is involved in hypoxia-induced pulmonary vasoconstriction. , 2001, American journal of respiratory cell and molecular biology.
[81] N. Voelkel,et al. Gene Expression Patterns in the Lungs of Patients With Primary Pulmonary Hypertension: A Gene Microarray Analysis , 2001, Circulation research.
[82] P. Huang,et al. Relative contributions of endothelial, inducible, and neuronal NOS to tone in the murine pulmonary circulation. , 1999, American journal of physiology. Lung cellular and molecular physiology.
[83] J. Parrillo,et al. Cytoplasmic redox potential affects energetics and contractile reactivity of vascular smooth muscle. , 1997, Journal of molecular and cellular cardiology.
[84] L B Sheiner,et al. Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.
[85] I Royston,et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.
[86] D. DeMets,et al. Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.
[87] P. Ganz,et al. Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. , 1996, Circulation.
[88] J. Mccormack,et al. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. , 1996, Circulation.
[89] S. Said,et al. VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells. , 1995, The American journal of physiology.
[90] Jesse D. Roberts,et al. Continuous nitric oxide inhalation reduces pulmonary arterial structural changes, right ventricular hypertrophy, and growth retardation in the hypoxic newborn rat. , 1995, Circulation research.
[91] N. Voelkel,et al. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. , 1994, American journal of respiratory cell and molecular biology.
[92] S. Pocock,et al. Factorial trials in cardiology: pros and cons. , 1994, European heart journal.
[93] B. Groves,et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.
[94] P. Chinn,et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.
[95] R. Rossaint,et al. Inhaled nitric oxide: its effects on pulmonary circulation and airway smooth muscle cells. , 1993, European heart journal.
[96] M. Abrahamowicz,et al. Randomized discontinuation trials: utility and efficiency. , 1993, Journal of clinical epidemiology.
[97] R. Rossaint,et al. Inhaled nitric oxide for the adult respiratory distress syndrome. , 1993, The New England journal of medicine.
[98] S. Abman,et al. Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. , 1990, The American journal of physiology.
[99] S. Yusuf,et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.
[100] P. Stacpoole. The pharmacology of dichloroacetate. , 1989, Metabolism: clinical and experimental.